Kobayashi Pharmaceutical Co., Ltd.

TSE:4967 Stock Report

Market Cap: JP¥423.7b

Kobayashi Pharmaceutical Valuation

Is 4967 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4967 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
JP¥5.31k
Fair Value
7.3% overvalued intrinsic discount
8
Number of Analysts

Below Fair Value: 4967 (¥5700) is trading above our estimate of fair value (¥5311.88)

Significantly Below Fair Value: 4967 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4967?

Key metric: As 4967 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 4967. This is calculated by dividing 4967's market cap by their current earnings.
What is 4967's PE Ratio?
PE Ratio42.1x
EarningsJP¥10.07b
Market CapJP¥423.73b

Price to Earnings Ratio vs Peers

How does 4967's PE Ratio compare to its peers?

The above table shows the PE ratio for 4967 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average31.7x
4922 KOSÉ
48.6x19.8%JP¥364.6b
4927 Pola Orbis Holdings
41.6x12.8%JP¥304.8b
4527 Rohto PharmaceuticalLtd
18.2x11.4%JP¥539.9b
4928 Noevir Holdings
18.5x2.0%JP¥147.0b
4967 Kobayashi Pharmaceutical
42.1x17.3%JP¥423.7b

Price-To-Earnings vs Peers: 4967 is expensive based on its Price-To-Earnings Ratio (42.1x) compared to the peer average (31.7x).

Price to Earnings Ratio vs Industry

How does 4967's PE Ratio compare vs other companies in the JP Personal Products Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
4967 42.1xIndustry Avg. 24.9xNo. of Companies4PE01632486480+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 4967 is expensive based on its Price-To-Earnings Ratio (42.1x) compared to the JP Personal Products industry average (24.8x).

Price to Earnings Ratio vs Fair Ratio

What is 4967's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4967 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio42.1x
Fair PE Ratio32.5x

Price-To-Earnings vs Fair Ratio: 4967 is expensive based on its Price-To-Earnings Ratio (42.1x) compared to the estimated Fair Price-To-Earnings Ratio (32.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 4967 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentJP¥5,700.00
JP¥5,943.75
+4.3%
9.8%JP¥7,000.00JP¥4,900.00n/a8
Feb ’26JP¥5,790.00
JP¥5,943.75
+2.7%
9.8%JP¥7,000.00JP¥4,900.00n/a8
Jan ’26JP¥6,230.00
JP¥5,943.75
-4.6%
9.8%JP¥7,000.00JP¥4,900.00n/a8
Dec ’25JP¥5,960.00
JP¥5,850.00
-1.8%
10.4%JP¥7,000.00JP¥4,900.00n/a8
Nov ’25JP¥5,530.00
JP¥5,806.25
+5.0%
10.6%JP¥7,000.00JP¥4,900.00n/a8
Oct ’25JP¥5,747.00
JP¥5,721.43
-0.4%
11.3%JP¥7,000.00JP¥4,800.00n/a7
Sep ’25JP¥5,600.00
JP¥5,941.43
+6.1%
12.1%JP¥7,000.00JP¥4,800.00n/a7
Aug ’25JP¥5,904.00
JP¥5,941.43
+0.6%
12.1%JP¥7,000.00JP¥4,800.00n/a7
Jul ’25JP¥5,300.00
JP¥5,941.43
+12.1%
12.1%JP¥7,000.00JP¥4,800.00n/a7
Jun ’25JP¥5,429.00
JP¥6,348.33
+16.9%
7.0%JP¥7,000.00JP¥5,800.00n/a6
May ’25JP¥5,420.00
JP¥6,898.33
+27.3%
15.7%JP¥9,000.00JP¥5,800.00n/a6
Apr ’25JP¥4,969.00
JP¥8,181.67
+64.7%
17.0%JP¥10,400.00JP¥6,540.00n/a6
Mar ’25JP¥5,982.00
JP¥8,256.67
+38.0%
15.9%JP¥10,400.00JP¥6,750.00n/a6
Feb ’25JP¥6,725.00
JP¥8,531.25
+26.9%
14.4%JP¥10,400.00JP¥6,800.00JP¥5,790.008
Jan ’25JP¥6,790.00
JP¥8,464.29
+24.7%
15.4%JP¥10,400.00JP¥6,800.00JP¥6,230.007
Dec ’24JP¥6,770.00
JP¥8,860.00
+30.9%
17.4%JP¥11,400.00JP¥6,800.00JP¥5,960.008
Nov ’24JP¥6,226.00
JP¥8,835.00
+41.9%
17.4%JP¥11,400.00JP¥6,800.00JP¥5,530.008
Oct ’24JP¥6,675.00
JP¥8,835.00
+32.4%
17.4%JP¥11,400.00JP¥6,800.00JP¥5,747.008
Sep ’24JP¥7,227.00
JP¥9,115.00
+26.1%
15.4%JP¥11,400.00JP¥6,800.00JP¥5,600.008
Aug ’24JP¥7,755.00
JP¥9,158.75
+18.1%
15.3%JP¥11,400.00JP¥7,600.00JP¥5,904.008
Jul ’24JP¥7,821.00
JP¥9,158.75
+17.1%
15.3%JP¥11,400.00JP¥7,600.00JP¥5,300.008
Jun ’24JP¥7,880.00
JP¥9,075.00
+15.2%
16.5%JP¥11,400.00JP¥7,500.00JP¥5,429.008
May ’24JP¥8,480.00
JP¥9,112.50
+7.5%
16.6%JP¥11,400.00JP¥7,500.00JP¥5,420.008
Apr ’24JP¥8,090.00
JP¥9,285.71
+14.8%
16.6%JP¥11,400.00JP¥7,500.00JP¥4,969.007
Mar ’24JP¥8,110.00
JP¥9,351.43
+15.3%
16.7%JP¥11,600.00JP¥7,600.00JP¥5,982.007
Feb ’24JP¥9,190.00
JP¥9,337.14
+1.6%
16.0%JP¥11,600.00JP¥7,700.00JP¥6,725.007
Analyst Price Target
Consensus Narrative from 8 Analysts
JP¥5.94k
Fair Value
4.1% undervalued intrinsic discount
8
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/15 04:24
End of Day Share Price 2025/02/14 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Kobayashi Pharmaceutical Co., Ltd. is covered by 19 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mitsuko MiyasakoBarclays
Ritsuko TsunodaBofA Global Research
Daisuke YamaguchiCitigroup Global Markets Japan Inc.